Introduction {#sec1-1}
============

Bone marrow mesenchymal stem cells (BMSCs) are one of the main sources of endogenous stem cells. They are a type of multi-potent cell with non-immunogenic capacity and are ideal seed cells for gene and cell therapy. Moreover, BMSCs have strong mobilizing effects and increase the potential value of cells for clinical applications (Maijenburg et al., 2011; Zhang et al., 2012). There is evidence that when cerebral ischemia occurs, BMSCs are mobilized from the bone marrow to the focal point through peripheral circulation and initiate tissue regeneration (Maijenburg et al., 2011). The agents of mobilization multiply and drive stem cells from the bone marrow pool to the circulating pool and then enable stem cells to enter the blood circulation through the basilar membrane and vascular endothelium (Zhang, 2011). However, there are three unsolved problems: an insufficient number of homing BMSCs differentiate into specific neurons for functional repair; the low survival rate of homing BMSCs in the infarct area; and most homing BMSCs die within 7 days because of a lack of blood supply and insufficient nutrition in the infarct area. Therefore, a valid method is needed to stimulate neovascularization in the infarct area and increase the survival rate of BMSCs (Qiu and Jin, 2008; Roemeling-van Rhijn et al., 2012). The key to realizing stem cell therapy in clinical applications is to encourage more BMSCs into the bloodstream. Some traditional Chinese medicines have proved useful in the mobilization of stem cells (Wang et al., 2009; Yuan et al., 2012). Activating blood and resolving blood stasis is effective for stem cell homing from multiple aspects; it can improve the microenvironment of the infarct area, increase the survival rate of stem cells in the infarct area and promote the differentiation of stem cells into nerve cells (Zhang et al., 2014a). Panax notoginseng saponins (PNS), one of the main chemical constituents of *Xuesaitong* capsules (Zhang et al., 2014b), can decrease intracellular adhesion molecule-1 expression and increase vascular endothelial growth factor and vascular endothelial growth factor receptor expression in the peripheral blood of patients with acute cerebral infarction (Guo and Li, 2010; Huang et al., 2014) and improve neurological function deficits after cerebral ischemia. We investigated the effects of PNS on the mobilization of BMSCs after cerebral infarction.

Materials and Methods {#sec1-2}
=====================

Experimental animals {#sec2-1}
--------------------

Two hundred healthy specific pathogen-free grade adult male Sprague-Dawley rats weighing 280--300 g and aged 3 months were purchased from Beijing Vital River Company, China (license No. SCXK (Jing) 2006-0009) and used in this study. All rats were raised for 1 week at the Experimental Animal Center, Henan University of Traditional Chinese Medicine, China before use. They were randomly divided into five groups with 40 rats per group: normal, middle cerebral artery occlusion (MCAO), and low-, middle-, and high-dose *Xuesaitong* groups. All animal experiments were approved by the Animal Ethics Committee. All efforts were made to minimize the suffering and number of rats used in this study.

Establishment of MCAO rat models {#sec2-2}
--------------------------------

MCAO was induced by a method described by Longa et al. (1989). Rats were anesthetized with chloral hydrate (35 mg/100 g, i.p.). A median incision was cut on the neck to expose the left common carotid (CCA), external carotid artery (ECA) and internal carotid artery (ICA). A nylon thread was carefully inserted from the CCA into the ICA and advanced towards the origin of the middle cerebral artery until a slight resistance was felt. The thread was inserted towards the bifurcation of the ICA and ECA at a depth of 18 ± 0.5 mm. After 2 hours of MCAO, the intraluminal filament was withdrawn until a slight resistance was felt. This indicated that the tip of the nylon thread was back to the ICA and that reperfusion was accomplished. After recovering from anesthesia, the rats were continuously given penicillin 40,000 units (i.m.) for 3 days during which sufficient food and water were provided. Rats that met all of the following criteria were included for further experiments: survived the first 24 hours after surgery; weight decreased after 24 hours; left Horner\'s syndrome; and right neurologic impairment.

Drug administration {#sec2-3}
-------------------

*Xuesaitong* capsules (main ingredient: PNS, 100 mg/capsule; batch No. Z20040016) were purchased from Kunming Pharmaceutical Corporation (KPC, Kunming, Yunnan Province, China) and dissolved into normal saline at concentrations of 20, 40 and 60 mg/mL.

One day after MCAO induction, rats in the normal and MCAO groups were administered normal saline (1 mL/100 g, i.g.) every day. Rats in the low-, middle- and high-dose *Xuesaitong* groups were administered *Xuesaitong* (20, 40, 60 mg/mL, i.g., respectively) until all rats were sacrificed.

Harvesting peripheral blood and bone marrow {#sec2-4}
-------------------------------------------

At 1, 3, 7, 14 and 28 days after MCAO induction, eight rats per group were selected for harvesting peripheral blood and plasma. The blood and plasma were collected from the abdominal aorta. Plasma was used for enzyme-linked immunosorbent assay and blood for flow cytometry. Rats were sacrificed and the thigh bone was exposed. The bone marrow of the thigh bone was flushed out with buffer (3.8 mL of Dulbecco\'s modified Eagle\'s medium and 0.2 mL of heparin sodium). The samples were then filtered through 40-μm mesh filters and centrifuged at 1,500 r/min for 10 minutes. The supernatant was then collected and kept at --80°C. Sediments were diluted with 250 μL of PBS and recollected for testing.

ELISA assay {#sec2-5}
-----------

The levels of stem cell factors (SCF) in plasma and bone marrow were measured using ELISA kits. The measurements were performed step-by-step as outlined in the protocol booklet of the ELISA kit (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and according to the manufacturer\'s specification.

Flow cytometry assay {#sec2-6}
--------------------

Approximately 50 μL of plasma or bone marrow liquid was placed into the flow cytometry chamber (BD Pharmingen, San Diego, CA, USA). CD106-PE, CD54-FITC, CD117-FITC (Beijing Solarbio Science & Technology Co., Ltd., China) and control reagent were added afterwards. 1 × 10^5^ cells were counted in each sample and the percentages of CD54, CD106, and CD117-positive cells were calculated using CellQuest Pro software (Olympus, Tokyo, Japan).

Statistical analyses {#sec2-7}
--------------------

All collected data were analyzed using statistical software SPSS Version 17.0 (SPSS, Chicago, IL, USA). Analysis of variance (ANOVA) was used to find the significance of study parameters between groups. All results were expressed as the mean ± SD. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Effect of PNS on the SCF levels in plasma and bone marrow in rats with cerebral infarction {#sec2-8}
------------------------------------------------------------------------------------------

SCF levels in plasma and bone marrow were significantly higher in MCAO, low-, middle-, and high-dose *Xuesaitong* groups compared with the normal group (*P* \< 0.05). Plasma and bone marrow SCF levels in the MCAO group began to increase 1 day after MCAO, reached a peak at 14 days after MCAO, and gradually decreased thereafter. Plasma and bone marrow SCF levels in the middle- and high-dose *Xuesaitong* groups increased significantly compared with the MCAO group. There was no significant difference in plasma and bone marrow SCF level between low-dose *Xuesaitong* and MCAO groups (*P* \> 0.05; **[Figure 1](#F1){ref-type="fig"}**).

![Effect of *Xuesaitong* (Panax notoginseng saponins \[PNS\]) on stem cell factor (SCF) level in plasma and bone marrow of rats with cerebral infarction.\
Data are expressed as the mean ± SD of eight rats per group per time point. Analysis of variance (ANOVA) was used to determine the significant difference between groups. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. MCAO group. MCAO: Middle cerebral artery occlusion.](NRR-11-292-g002){#F1}

Effect of PNS on the number of CD54- and CD106-positive cells in plasma and bone marrow of rats with cerebral infarction {#sec2-9}
------------------------------------------------------------------------------------------------------------------------

Flow cytometry results showed that the number of CD54- and CD106-positive cells in plasma and bone marrow of rats in the MCAO, low-, middle-, and high-dose *Xuesaitong* groups was significantly higher than in the normal group (*P* \< 0.05). The number of CD54- and CD106-positive cells in plasma and bone marrow of rats in the MCAO and low-, middle-, and high-dose *Xuesaitong* groups increased to a peak level 1 day after MCAO and then gradually reduced thereafter. At different time points, the number of CD54- and CD106-positive cells in plasma and bone marrow in the middle- and high-dose *Xuesaitong* groups was significantly lower than that in the MCAO group, and the reduction in the low-dose *Xuesaitong* group was the most significant (*P* \< 0.05). There was no significant difference in the number of CD54- and CD106-positive cells in plasma and bone marrow between low-dose *Xuesaitong* and MCAO groups at each time point (*P* \> 0.05; **Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}**).

![Effect of *Xuesaitong* (Panax notoginseng saponins \[PNS\]) on the number of CD54-positive cells in plasma and bone marrow of rats with cerebral infarction.\
(A) Flow cytometry analysis on the number of CD54-positive cells in rat plasma and bone marrow. (B) Effect of PNS on CD54-positive cell percentage in rat plasma and bone marrow. Data are expressed as the mean ± SD of eight rats per group per time point. Analysis of variance (ANOVA) was used to determine the significant difference between groups. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. MCAO (ischemia) group. MCAO: Middle cerebral artery occlusion; XST: *Xuesaitong*.](NRR-11-292-g003){#F2}

![Effect of *Xuesaitong* (Panax notoginseng saponins \[PNS\]) on the number of CD106-positive cells in plasma and bone marrow of rats with cerebral infarction.\
(A) Flow cytometry analysis on the number of CD106-positive cells in rat plasma and bone marrow. (B) Effect of PNS on CD106-positive cell percentage in rat plasma and bone marrow. Data are expressed as the mean ± SD of eight rats per group per time point. Analysis of variance (ANOVA) was used to determine the significant difference between groups. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. MCAO group. MCAO: Middle cerebral artery occlusion; XST: *Xuesaitong*.](NRR-11-292-g004){#F3}

Effect of PNS on the number of CD117-positive cells in plasma and bone marrow of rats with cerebral infarction {#sec2-10}
--------------------------------------------------------------------------------------------------------------

Flow cytometry results showed that the number of CD117-positive cells in plasma and bone marrow of rats in the MCAO, low-, middle-, and high-dose *Xuesaitong* groups was significantly higher than in the normal group (*P* \< 0.05). Plasma and bone marrow SCF levels in the MCAO group began to increase 1 day after MCAO and reached a peak at 14 days. The number of CD117-positive cells gradually decreased thereafter. The number of plasma and bone marrow CD117-positive cells in the middle- and high-dose *Xuesaitong* groups increased more significantly than in the MCAO group. There was no significant difference in the number of CD117-positive cells in plasma and bone marrow between low-dose *Xuesaitong* and MCAO groups (*P* \> 0.05; **[Figure 4](#F4){ref-type="fig"}**).

![Effect of *Xuesaitong* (Panax notoginseng saponins \[PNS\]) on the number of CD117-positive cells in plasma and bone marrow of rats with cerebral infarction. (A) Flow cytometry analysis on the number of CD117-positive cells in rat plasma and bone marrow. (B) Effect of PNS on CD117-positive cell percentage in rat plasma and bone marrow. Data are expressed as the mean ± SD of eight rats per group per time point. Analysis of variance (ANOVA) was used to determine the significant difference between groups. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. MCAO group. MCAO: Middle cerebral artery occlusion; XST: *Xuesaitong*.](NRR-11-292-g005){#F4}

Discussion {#sec1-4}
==========

Recently, multiple factors such as chemotactic factors, growth factors and adhesion molecules have been discovered to be involved in the mobilization of BMSCs. However, tissue damage and external effects such as drugs can interfere with the process of mobilization. SCFs are considered to be one of the most powerful agents of mobilization and can drive more stem cells into plasma and greatly contribute to stem cell migration, accumulation and multiplication (Li et al., 2011; Baker et al., 2013).

Adhesion molecules such as CD106 and CD54 are common surface receptors of BMSCs that mediate the adhesion of hematopoietic cells and play an important role in information transmission between the two. Wang and Cheng (2009) discovered an obvious increase in serum CD106 and CD54 in patients with acute cerebral ischemia. The difference in serum CD106 and CD54 levels in the recovery phase remained significant compared with the control group. In addition, increased levels of CD106 and CD54 were positively correlated with the size of the infarct area. Yuan et al. (2012) found that the components of *Yangxintongmai*, an effective recipe for treatment of blood stasis syndrome of cardiovascular disease, could mobilize BMSCs into plasma and guide them to the myocardium infarct.

Our study showed that PNS stimulated the production of SCF from bone marrow and promoted the mobilization of BMSCs into plasma by reducing the adhesion effects of adhesion molecules on BMSCs. This phenomenon supports the traditional Chinese medicine theory of promoting blood circulation to remove blood stasis and thereby initiating tissue regeneration (Zhang, 2012a, b).
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